Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$3.52 - $5.46 $229,204 - $355,527
-65,115 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$5.1 - $7.0 $332,086 - $455,805
65,115 New
65,115 $338,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Resolute Capital Asset Partners LLC Portfolio

Follow Resolute Capital Asset Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resolute Capital Asset Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Resolute Capital Asset Partners LLC with notifications on news.